

Andrea DÃ-az-Tejedor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7565320/publications.pdf>

Version: 2024-02-01

6
papers

114
citations

1683354

5
h-index

2053342

5
g-index

6
all docs

6
docs citations

6
times ranked

268
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. <i>Haematologica</i> , 2020, 105, e116-e120.	1.7	38
2	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. <i>Cells</i> , 2019, 8, 1432.	1.8	24
3	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. <i>Cancers</i> , 2021, 13, 1353.	1.7	22
4	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	1.7	19
5	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2743.	1.7	9
6	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. <i>Cells</i> , 2021, 10, 559.	1.8	2